The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

The present application belongs to the field of life health, and discloses a sugar chain and a composition thereof, and use in the prevention and/or treatment of coronavirus infection. The sugar chain contains any one or more of Neu5Acα2-N.sub.1Gal building blocks, and/or any one or more of xFuc-N.sub.1Gal-N.sub.1(xFuc-N.sub.1)GlcNAc building blocks, at the non-reducing end, where, x=0 or 1, and N.sub.1=1, 2, 3, 4 or 6. A glycosidic bond formed between Neu5Ac and Gal is an α2 glycosidic bond. In the xFuc-N.sub.1Gal-N.sub.1(xFuc-N.sub.1)GlcNAc building blocks, a glycosidic bond formed between any two adjacent monosaccharides is an α1 or β1 glycosidic bond. The specific building block contained at the non-reducing end of the sugar chain blocks the binding of the virus to the host, thereby blocking virus invasion and infection of the respiratory tract/lung, and achieving the specific prevention and treatment.

The present application belongs to the field of life health, and discloses a sugar chain and a composition thereof, and use in the prevention and/or treatment of coronavirus infection. The sugar chain contains any one or more of Neu5Acα2-N.sub.1Gal building blocks, and/or any one or more of xFuc-N.sub.1Gal-N.sub.1(xFuc-N.sub.1)GlcNAc building blocks, at the non-reducing end, where, x=0 or 1, and N.sub.1=1, 2, 3, 4 or 6. A glycosidic bond formed between Neu5Ac and Gal is an α2 glycosidic bond. In the xFuc-N.sub.1Gal-N.sub.1(xFuc-N.sub.1)GlcNAc building blocks, a glycosidic bond formed between any two adjacent monosaccharides is an α1 or β1 glycosidic bond. The specific building block contained at the non-reducing end of the sugar chain blocks the binding of the virus to the host, thereby blocking virus invasion and infection of the respiratory tract/lung, and achieving the specific prevention and treatment.

The present invention relates to a method for drying human milk oligosaccharides (HMOs). More specifically, the present invention is related to a method of roller drying or drum drying of human milk oligosaccharides in a simple and economical way.

The invention relates to brartemicin analogues of Formula (IV) and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants. ##STR00001##

The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.

The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.

Disclosed is a method for the manufacture of a spray-dried powder consisting essentially of 3-fucosyllactose, the spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions containing the spray-dried powder.

The present invention relates to new synthetic molecules with agonist activity of human Toll-like Receptor 4 (TLR4), compositions comprising them and uses thereof for the treatment of diseases in which it is useful to induce or increase an immune response. The compounds have general formula (1), wherein R.sub.1 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═0 on C.sub.1, said chain being free from —OH substituents on C.sub.3, wherein R.sub.2 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═O on C.sub.1, said chain being free from —OH substituents on C.sub.3, wherein R.sub.3 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═O on C.sub.1, said chain being free from —OH substituents on C.sub.3; wherein R.sub.4 is a hydrogen atom (H) or a phosphate group (PO.sub.4.sup.2−).

##STR00001##

The present invention relates to new synthetic molecules with agonist activity of human Toll-like Receptor 4 (TLR4), compositions comprising them and uses thereof for the treatment of diseases in which it is useful to induce or increase an immune response. The compounds have general formula (1), wherein R.sub.1 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═0 on C.sub.1, said chain being free from —OH substituents on C.sub.3, wherein R.sub.2 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═O on C.sub.1, said chain being free from —OH substituents on C.sub.3, wherein R.sub.3 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═O on C.sub.1, said chain being free from —OH substituents on C.sub.3; wherein R.sub.4 is a hydrogen atom (H) or a phosphate group (PO.sub.4.sup.2−).

##STR00001##